Louis Plamondon, Ph.D.

Dr. Louis Plamondon is Vice President of CMC, leading the development of small molecule drugs. He initiates and leads all pre-development/development activities including non-GMP production of API/Drug Product for pre-clinical studies, production of IND-enabling toxicology material, and cGMP manufacturing of drug substances and drug products. His scope of responsibilities span from enabling Phase I studies through global registrational application and also includes commercial manufacturing and launch activities. Louis is in charge of establishing clinical and commercial supply chain strategies, vendor and alliance management, portfolio strategy implementation, developing regulatory strategies & interacting with regulators, developing life-cycle management strategies & generating intellectual property to extend product life-cycle. Louis joined Constellation as Executive Director in 2015. During his career, Louis has led cross-functional teams across multiple programs and is a co-inventor and leader for VelcadeĀ® (bortezomib), a new chemical entity and the first proteasome inhibitor approved for the treatment of patients with multiple myeloma. Louis received his Ph.D. in Organic Chemistry from University of Montreal under the guidance of James D. Wuest and completed his postdoctoral fellowship at Harvard University under the guidance of Stuart L. Schreiber.